Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01208051 · ClinicalTrials.gov registry record · Phase 1
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 127
- Enrollment target
NCT01208051: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01208051 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 127 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01208051, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 127 participants
- Enrollment target
Study Summary
This partially randomized phase I/II trial studies the side effects and best dose of cediranib maleate when given together with or without lenalidomide and to see how well they work in treating patients with thyroid cancer. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of thyroid cancer by blocking blood flow to the tumor. It is not yet known whether cediranib maleate is more effective when given together with lenalidomide in treating thyroid cancer.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Lenalidomide
- DRUG Cediranib
- DRUG Cediranib Maleate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2010-09-09 |
| Est. Completion | 2020-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01208051
The ClinicalTrials.gov registry entry for NCT01208051 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01208051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01208051 about?
NCT01208051 is a clinical study titled "Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer". This partially randomized phase I/II trial studies the side effects and best dose of cediranib maleate when given together with or without lenalidomide and to see how well they work in treating patients with thyroid cancer. Cediranib maleate may stop the growth of tumor cells by blocking some of the...
What is the current status of trial NCT01208051?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 127 participants. The study started on 2010-09-09. Estimated completion is 2020-02-01.
What interventions are being tested in trial NCT01208051?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Lenalidomide (DRUG), Cediranib (DRUG), Cediranib Maleate (DRUG).
Who is sponsoring clinical trial NCT01208051?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.